There have been promising preliminary results from the ongoing ASPIRE study (NCT01080391), a Phase III clinical trial for patients with relapsed refractory multiple myeloma. From the British Oncology Pharmacy Association (BOPA) 20th Annual Symposium 2017 in Glasgow, UK, Alberto Rocci, MD from Central Manchester University Hospital, Manchester, UK gives an overview of the study, an update on the results so far and discusses the toxicity profile of the treatment, which includes carfilzomib. This content has been supported by Napp Pharmaceuticals through an unrestricted educational grant to Magdalen Medical Publishing. The company has had no influence on the production of the content.
